TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is poised for future growth, fueled by strong clinical data for its approved drug BRIUMVI, impressive revenue growth and an expanding market share, and a strong financial position with a net raise of $500M in cash and equivalents in the past quarter and increased revenue guidance for FY 2026. Our conservative estimates suggest a potential upside in stock value, but risks include potential safety or efficacy concerns, increased competition, regulatory challenges, and intellectual property issues.

TG Therapeutics is a fully integrated biotech company with a research pipeline and FDA-approved treatment for relapsing forms of multiple sclerosis. However, their recent approval for a new IV dosing regimen may not provide a significant advantage compared to their competitor, Ocrevus, as patient and physician preferences for a streamlined infusion process may not outweigh the influence of payer coverage. Additionally, while the company plans to expand into other autoimmune indications, it is uncertain if these potential treatments will contribute significant value to their financials in the near future.